APR-017 and APR-246 are first-in-class drugs, capable of binding to cysteine residues in the DNA binding domain of p53, restoring its physiological conformation in TP53 mutated in vitro models of CLL [126,127]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.